抗血栓药物及逆转策略对创伤性急性硬膜下血肿手术治疗与结局的影响
回顾性研究纳入138例需手术清除的创伤性急性硬膜下血肿患者,比较服用抗凝药并接受药物逆转、服用抗血小板药并接受血小板输注及未服用抗血栓药三组结局。抗血小板药加血小板输注组术中时间更长且姑息治疗会诊率更高,其余结局无显著差异。
要点
- 服用抗血小板药并接受血小板输注者术中时间较长、姑息治疗会诊率较高。
- 接受抗血栓逆转者与未服用抗血栓药者结局相当。
- 多变量分析中抗血小板药加血小板输注组术中时间仍最长。
核心结论
- 服用抗血小板药并接受血小板输注的创伤性急性硬膜下血肿手术患者术中操作时间更长、姑息治疗会诊率更高;接受抗血栓逆转者与未服用抗血栓药者结局相当。
研究设计与样本
- 回顾性研究纳入138例需手术清除的创伤性急性硬膜下血肿患者,按抗血栓药物使用及是否接受药物逆转或血小板输注分组,进行三组结局比较,并用多变量回归校正损伤严重程度。
主要发现
- 138例中,13.0%(n=18)服用抗凝药,16.7%(n=23)服用抗血小板药,3.6%(n=5)两者均服用。
- 服用抗血小板药并接受血小板输注者较服用抗凝药并接受药物逆转者及未服用抗血栓药者术中时间更长(P=0.040)、姑息治疗会诊率更高(P=0.046)。
- 各组间院内颅内出血和静脉血栓栓塞频率、住院时间、住院死亡率及随访健康状况无显著差异。
- 多变量分析中,抗血小板药加血小板输注组术中时间仍最长,其他结局与患者分组无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Careful hematologic management is required in surgical patients with traumatic acute subdural hematoma (aSDH) taking antithrombotic medications. We sought to compare outcomes between patients with aSDH taking antithrombotic medications at admission who received antithrombotic reversal with patients with aSDH not taking antithrombotics. METHODS: Retrospective review identified patients with traumatic aSDH requiring surgical evacuation. The cohort was divided based on antithrombotic use and whether pharmacologic reversal agents or platelet transfusions were administered. A 3-way comparison of outcomes was performed between patients taking anticoagulants who received pharmacologic reversal, patients taking antiplatelets who received platelet transfusion, and patients not taking antithrombotics. Multivariable regressions, adjusted for injury severity, further investigated associations with outcomes. RESULTS: Of 138 patients who met inclusion criteria, 13.0% (n = 18) reported taking anticoagulants, 16.7% (n = 23) reported taking antiplatelets, and 3.6% (n = 5) reported taking both. Patients taking antiplatelets who received platelet transfusion had longer intraoperative times (P = 0.040) and higher rates of palliative care consultations (P = 0.046) compared with patients taking anticoagulants who received pharmacologic reversal and patients not taking antithrombotics. Across groups, no significant differences were found in frequency of in-hospital intracranial hemorrhage and venous thromboembolism, length of hospital stay, rate of inpatient mortality, or follow-up health status. In multivariable analysis, intraoperative time remained longest for the antiplatelets with platelet transfusion group. Other outcomes were not associated with patient group. CONCLUSIONS: Among surgical patients with traumatic aSDH, those taking antiplatelet medications who receive platelet transfusions experience longer intraoperative procedure times and higher rates of palliative care consultation. Comparable outcomes were observed between patients receiving antithrombotic reversal and patients not taking antithrombotics.
引用
- Vattipally VN, Ran KR, Giwa GA, et al. Impact of Antithrombotic Medications and Reversal Strategies on the Surgical Management and Outcomes of Traumatic Acute Subdural Hematoma. World Neurosurg. 2023. PMID: 38030067. doi:10.1016/j.wneu.2023.11.117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。